Valerie Yang: Are We Over-Treating Some Lymphomas?
Valerie Yang, Consultant Medical Oncologist, National Cancer Centre Singapore, shared a post on LinkedIn:
“Hot off the press: Are We Over-Treating Some Lymphomas? It seems so!
Angioimmunoblastic T-cell lymphoma (AITL) is a type of nodal T follicular helper (nTFH) lymphoma that is rare and widely considered to be highly aggressive. This disease is typically considered fatal without intensive multi-agent chemotherapy, which is invariably offered to patients upon diagnosis.
We report, for the first time, a series of nine patients with AITL who lived for years without chemotherapy. This therefore challenges status quo and raises the question: could a less aggressive approach be appropriate for certain patients?
In this series, we delineate their clinical presentation, histologic patterns and results of targeted sequencing. None of the commonly mutated genes TET2, DNMT3A, or IDH2 known to be associated with survival in this disease were aberrant.
We propose that not all patients with nTFH cell lymphoma require multiagent chemotherapy in first-line treatment and some can have excellent long-term outcomes. We should identify specific patients with nTFH cell lymphoma of an indolent nature and determine if deferring initial treatment can lead to similar or even better outcomes.
Grateful for the friendship and collaboration with Jie Wang and Jadee Neff at Duke University Health System and our whole team. Chee Leong Cheng, Jing Quan Lim, Jason Yongsheng Chan, Soon Thye LIM, Choon Kiat Ong. More information to come as we uncover more about this challenging lymphoma!”
Indolent nodal T follicular helper cell lymphomas—A case series
Authors: Jie Wang, Chun En Yau, Chen Ee Low, Mohamed Haniffa Bin Hasan Mohamed, Chee Leong Cheng, Jadee L. Neff, Jing Quan Lim, Soon Thye Lim, Jason Yongsheng Chan, Choon Kiat Ong and Valerie Shiwen Yang
More posts featuring Valerie Yang.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023